Amendments to the Claims:

1. (Original) A compound of the formula (I):



(I)

wherein

R^1 and R^2 independently represent a hydrogen atom, a halogen atom, an alkyl group having from 1 to 6 carbon atoms, an alkoxy group having from 1 to 6 carbon atoms, a cyano group, an alkanoyl group having from 1 to 6 carbon atoms, a haloalkyl group having from 1 to 6 carbon atoms, or a haloalkoxy group having from 1 to 6 carbon atoms;

X represents a covalent bond, an alkylene group having from 1 to 3 carbon atoms, an alkylene group having from 1 to 3 carbon atoms substituted by a hydroxy group or an oxo group; a methyleneoxy group, an ethyleneoxy group, a methyleneoxymethylene group, an oxymethylene group, an ethyleneoxy group, oxy, imino, iminomethylene, iminoethylene, methyleneimino or ethyleneimino,

said imino groups are unsubstituted or are substituted by an alkyl group having from 1 to 6 carbon atoms;

A represents a bicyclic, aromatic, saturated or partially unsaturated heterocyclic or carbocyclic group having from 8 to 12 ring atoms;

said heterocyclic group contains either from 1 to 4 nitrogen atoms, or 1 or 2 nitrogen atoms and/or 1 or 2 oxygen or sulfur atoms,

said heterocyclic or carbocyclic group are unsubstituted or are substituted by at least one substituent selected from the group consisting of substituents α;

B represents a phenyl group or a heteroaryl group having from 5 to 6 ring atoms;

said phenyl groups and said heteroaryl groups having from 5 to 6 atoms are unsubstituted or are substituted by at least one substituent selected from the group consisting of substituents α;

said substituents α are selected from the group consisting of halogen atoms, alkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, cyano groups, alkanoyl groups having from 1 to 6 carbon atoms, haloalkyl groups having from 1 to 6 carbon atoms, oxo groups or haloalkoxy groups having from 1 to 6 carbon atoms;

or a pharmaceutically acceptable ester of such compound;
or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to Claim 1 wherein:
R^1 and R^2 independently represent a hydrogen atom or a fluorine atom.

3. (Original) A compound according to Claim 1 to 2, wherein:
X represents an alkylene group having from 1 to 2 carbon atoms, an alkylene group having from 1 to 2 carbon atoms substituted by a hydroxy group or an oxo group, a methyleneoxy group, an oxymethylene group, iminomethylene or methyleneimino, said imino groups are unsubstituted or are substituted by an alkyl group having from 1 to 6 carbon atoms.

4. (Original) A compound according to any one of Claims 1 to 3, wherein:
X represents an alkylene group having from 1 to 2 carbon atoms, an oxymethylene group or iminomethylene.

5. (Original) A compound according to any one of Claims 1 to 4, wherein
A represents a bicyclic aromatic heterocyclic group having from 8 to 10 ring atoms, said heterocyclic group contains either from 1 to 3 nitrogen atoms, or 1 nitrogen atom and/or 1 oxygen or atom.

6. (Original) A compound according to any one of Claims 1 to 5 wherein
A represents a benzimidazole group, a benzoisoxazole group, an indole group, an indazole group, a quinazolin group, an oxo-1*H*-benzimidazole group, an imidazopyridine group, a tetrahydroimidazopyridine group, or a quinoline group.

7. (Original) A compound according to any one of Claims 1 to 6 wherein
B represents an optionally substituted phenyl group.

8. (Original) A compound according to any one of Claims 1 to 6 wherein
B represents unsubstituted phenyl group or a fluorophenyl group.

9. (Original) A compound according to Claim 1 selected from:
N-[(2-benzyl-1*H*-benzimidazol-5-yl)methyl]-4-hydroxybenzamide;

4-hydroxy-*N*-{[1-(2-phenylethyl)-1*H*-benzimidazol-6-yl]methyl}benzamide;
N-[(2-benzyl-1*H*-indol-5-yl)methyl]-4-hydroxybenzamide;
4-hydroxy-*N*-{[1-(2-phenylethyl)-1*H*-indazol-6-yl]methyl}benzamide;
N-{[4-(Benzylamino)quinazolin-6-yl]methyl}-4-hydroxybenzamide;
4-hydroxy-*N*-{[2-methyl-1-(2-phenylethyl)-1*H*-benzimidazol-6-yl]methyl}benzamide;
N-{[4-(Benzyloxy)quinolin-6-yl]methyl}-4-hydroxybenzamide;
4-hydroxy-*N*-{[2-oxo-3-(2-phenylethyl)-2,3-dihydro-1*H*-benzimidazol-5-yl]methyl}benzamide;
4-hydroxy-*N*-{[3-(2-phenylethyl)-1*H*-indazol-5-yl]methyl}benzamide];
4-Hydroxy-*N*-{[3-(2-phenylethyl)imidazo[1,5-*a*]pyridin-6-yl]methyl}benzamide;
N-{[3-(benzyloxy)-1,2-benzisoxazol-5-yl]methyl}-4-hydroxybenzamide;
N-{[2-(2-fluorobenzyl)-1*H*-benzimidazol-6-yl]methyl}-4-hydroxybenzamide;
N-[(2-benzyl-5,6,7,8-tetrahydroimidazo[1,2-*a*]pyridin-7-yl)methyl]-4-hydroxybenzamide;
N-[(2-benzyl-1*H*-indol-5-yl)methyl]-3-fluoro-4-hydroxybenzamide; and
4-hydroxy-*N*-{[1-(2-phenylethyl)-1*H*-imidazo[4,5-*b*]pyridin-6-yl]methyl}benzamide;
or a pharmaceutically acceptable salt thereof.

10. (Original) A pharmaceutical composition, which comprises a compound according to any one of claims 1-9, or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, and a suitable pharmaceutically acceptable carrier.

11. (Original) A pharmaceutical composition for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor, in a mammalian subject, which comprises a therapeutically effective amount of a compound according to any one of claims 1-9, or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, and a suitable pharmaceutically acceptable carrier.

12. (Canceled)

13. (Canceled)